BioSpace News Archive

Voyager Therapeutics, Inc., a gene therapy company developing life-changing treatments and next-generation adeno-associated virus capsids, announced the appointment of Catherine J. Mackey, Ph.D. to its Board of Directors.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced a collaboration with the Kenya Medical Research Institute (KEMRI) to plan, seek regulatory approval for and conduct a Phase 1 clinical study in Kenya to develop TNX-8011 as a vaccine to protect against monkeypox and smallpox

Seattle-based Precision Oncology company SEngine Precision Medicine has now raised a total of $19M, following the recent closing of a $10M Series A2, as it continues to commercialize a platform that matches cancer patients to the right drug and also drives drug discovery.

Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced the addition of Liz Bhatt, MS, MBA, as Chief Operating Officer, and Ran Xiao as Vice President of Finance and Business.

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended June 30, 2022.

Animol Discovery, Inc., a pioneer in veterinary pharmaceutical discovery, announced it has raised $34.0 million in Series B financing.

Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the second quarter of 2022.

Passage Bio, Inc. today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 4, 2022, to report its second quarter 2022 financial results and discuss recent business highlights.

Dante Genomics, a global leader in genomics and precision medicine, today announced that members of its management team will participate in the Canaccord Genuity 42nd Annual Growth Conference.

Immutep Limited, a biotechnology company developing novel LAG-3-related immunotherapy treatments for cancer and autoimmune disease, provides an update on the ongoing development of its product candidates, eftilagimod alpha and IMP761 for the quarter ended 30 June 2022.